Rutgers,The State University of New Jersey, New Brunswick, U.S.A
UMDNJ U.S.A. (Post doctoral appointee)
Indian I.I.T Jodhpur, (Assistant Professor)
IISER Pune -Scientist-D
Tata Memorial Centre - Advanced Centre for Treatment, Research and Education of Cancer (ACTREC), Mumbai, India
My undergraduate training in Human Biology (Biochemistry Major) at A.I.I.M.S., New Delhi provided me the exposure to research methodology, and hands-on experience in experimental research. This experience highly motivated me to pursue a career in Biology and address questions at the interface of both basic and clinical sciences. I believe that detailed understanding of molecular mechanisms required for maintaining normal cell functions and the identification of key molecules whose alterations may result in development of diseases such as cancer are crucial for early detection and more effective therapeutic strategies. In this respect, I have been fortunate enough to work on research projects embarking upon understanding mechanisms underlying maintenance of genome integrity during my doctoral as well as post doctoral studies in the laboratory of Prof. Kim McKim, Rutgers University, NJ (2000-2006), and Dr. Brian Calvi, Syracuse University, NY (2007-2008) respectively. In 2009, I received a post doctoral fellowship from the New Jersey Commission for Cancer research to study the functions of novel components of the BRCA2 mediated DNA repair pathway in genome maintenance and their relevance in cancer in the laboratory of Dr. Zhiyuan Shen at the Cancer Institute of New Jersey.
Prior to joining ACTREC, I worked at IISER Pune (2014 -2016) first as a scientist at the Centre for Excellence for Epigenetics and then as a DBT-BioCARe scientist. I investigated the role of epigenetic factors involved in the regulation of key signaling pathways such as the Wnt pathway and maintenance of adult epithelium stem cell maintenance using both Drosophila and mammalian cells.
The Wellcome-Trust DBT India Alliance has provided me with the opportunity to address some of the unanswered questions regarding the role of a novel BRCA2 interacting protein called BCCIP which regulates the functions of two key tumor suppressor genes BRCA2 and p53. The critical review of my proposal during the application process has enabled me to fine tune my research design and the opportunity to work at ACTREC which will greatly facilitate my proposed objectives. The results from this study will provide important insights which will be relevant for treatment strategies for BCCIP deficient cancers and also explore the potential of BCCIP gene as diagnostic marker for cancer.